David Michael Madden

Adolor Corp. is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The company develops and commercializes of novel opioid receptor-targeted therapeutics designed to maintain or improve pain relief and reduce opioid-related side effects. Its commercial product ENTEREG is a small molecule, peripherally acting mu opioid receptor antagonist intended to block the adverse side effects of opioid analgesics like morphine, on the gastrointestinal tract without interfering with central nervous system and mediated analgesia. The company was founded in 1993 and is headquartered in Exton, PA.

Hospital for Special Surgery provides healthcare services. Its services include orthopedic, rheumatology, and rehabilitation specific surgery services. The company was founded by James A. Knight and Robert M. Hartley in 1863 and is headquartered in New York, NY.

Part of Sanofi, Selectide Corp. is a pharmaceutical research firm. The private company is based in Tucson, AZ. The company was founded by Stephen Ralfe Evans-Freke. Selectide was acquired by Marion Merrell Dow, Inc. on January 27, 1995 for $58 million.

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.

River Vision Development Corp. develops novel protein therapies. The firm provides therapy for the treatment of graves orbitopathy which is a condition in which an autoimmune response is mounted against tissues behind the eye, causing inflammation, tissue proliferation and excess production of extracellular matrix. The company was founded in 2011 and is headquartered in New York, NY.

Narrow River Management LP operates as a investment management company, which focuses on equity investments in the pharmaceutical industry. The company was founded by David M. Madden and is headquartered in New York, NY.

Pharmaceutical Partners LLC is an investment holding private company based in New York, NY.

Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA.